Advanced

Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes

Lund, S. S.; Tarnow, L.; Astrup, A. S.; Hovind, P.; Jacobsen, P. K.; Alibegovic, A. C.; Parving, I.; Pietraszek, L.; Frandsen, M. and Rossing, P., et al. (2009) In Diabetes, Obesity and Metabolism 11(10). p.966-977
Abstract
Background In addition to its glucose-lowering effect, metformin treatment has been suggested to improve lipidaemia in patients with type 2 diabetes. In contrast, in patients with type 1 diabetes (T1DM), information about the effect of metformin treatment on lipidaemia is limited. In this study, we report the effect of a 1-year treatment with metformin vs. placebo on plasma lipids in T1DM patients and persistent poor glycaemic control. Methods One hundred T1DM patients with haemoglobinA(1c) (HbA(1c)) >= 8.5% during the year before enrolment entered a 1-month run-in period on placebo treatment. Thereafter, patients were randomized (baseline) to treatment with either metformin (1000 mg twice daily) or placebo for 12 months (double... (More)
Background In addition to its glucose-lowering effect, metformin treatment has been suggested to improve lipidaemia in patients with type 2 diabetes. In contrast, in patients with type 1 diabetes (T1DM), information about the effect of metformin treatment on lipidaemia is limited. In this study, we report the effect of a 1-year treatment with metformin vs. placebo on plasma lipids in T1DM patients and persistent poor glycaemic control. Methods One hundred T1DM patients with haemoglobinA(1c) (HbA(1c)) >= 8.5% during the year before enrolment entered a 1-month run-in period on placebo treatment. Thereafter, patients were randomized (baseline) to treatment with either metformin (1000 mg twice daily) or placebo for 12 months (double masked). Patients continued ongoing insulin therapy and their usual outpatient clinical care. Outcomes were assessed at baseline and after 1 year. Results After 1 year, in those patients who did not start or stop statin therapy during the trial, metformin treatment significantly reduced total and LDL cholesterol by approximately 0.3 mmol/l compared with placebo (p = 0.021 and p = 0.018 respectively). Adjustment for statin use or known cardiovascular disease did not change conclusions. In statin users (metformin: n = 22, placebo: n = 13), metformin significantly lowered levels of LDL and non-HDL cholesterol by approximately 0.5 mmol/l compared with placebo (adjusted for changes in statin dose or agent: p = 0.048 and p = 0.033 respectively). HbA(1c) (previously reported) was not significant different between treatments. Conclusion In patients with poorly controlled T1DM, at similar glycaemic levels, adjunct metformin therapy during 1 year significantly lowered levels of proatherogenic cholesterolaemia independent of statin therapy. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cholesterol, LDL, statins, Type 1 diabetes mellitus, metformin, lipids
in
Diabetes, Obesity and Metabolism
volume
11
issue
10
pages
966 - 977
publisher
Wiley-Blackwell
external identifiers
  • wos:000269742300006
  • scopus:70349762895
ISSN
1462-8902
DOI
10.1111/j.1463-1326.2009.01079.x
language
English
LU publication?
yes
id
98b7d895-d603-4b53-b8f9-28362012f9de (old id 1492381)
date added to LUP
2009-10-16 15:46:39
date last changed
2017-10-01 03:50:16
@article{98b7d895-d603-4b53-b8f9-28362012f9de,
  abstract     = {Background In addition to its glucose-lowering effect, metformin treatment has been suggested to improve lipidaemia in patients with type 2 diabetes. In contrast, in patients with type 1 diabetes (T1DM), information about the effect of metformin treatment on lipidaemia is limited. In this study, we report the effect of a 1-year treatment with metformin vs. placebo on plasma lipids in T1DM patients and persistent poor glycaemic control. Methods One hundred T1DM patients with haemoglobinA(1c) (HbA(1c)) >= 8.5% during the year before enrolment entered a 1-month run-in period on placebo treatment. Thereafter, patients were randomized (baseline) to treatment with either metformin (1000 mg twice daily) or placebo for 12 months (double masked). Patients continued ongoing insulin therapy and their usual outpatient clinical care. Outcomes were assessed at baseline and after 1 year. Results After 1 year, in those patients who did not start or stop statin therapy during the trial, metformin treatment significantly reduced total and LDL cholesterol by approximately 0.3 mmol/l compared with placebo (p = 0.021 and p = 0.018 respectively). Adjustment for statin use or known cardiovascular disease did not change conclusions. In statin users (metformin: n = 22, placebo: n = 13), metformin significantly lowered levels of LDL and non-HDL cholesterol by approximately 0.5 mmol/l compared with placebo (adjusted for changes in statin dose or agent: p = 0.048 and p = 0.033 respectively). HbA(1c) (previously reported) was not significant different between treatments. Conclusion In patients with poorly controlled T1DM, at similar glycaemic levels, adjunct metformin therapy during 1 year significantly lowered levels of proatherogenic cholesterolaemia independent of statin therapy.},
  author       = {Lund, S. S. and Tarnow, L. and Astrup, A. S. and Hovind, P. and Jacobsen, P. K. and Alibegovic, A. C. and Parving, I. and Pietraszek, L. and Frandsen, M. and Rossing, P. and Parving, H. -H. and Vaag, Allan},
  issn         = {1462-8902},
  keyword      = {cholesterol,LDL,statins,Type 1 diabetes mellitus,metformin,lipids},
  language     = {eng},
  number       = {10},
  pages        = {966--977},
  publisher    = {Wiley-Blackwell},
  series       = {Diabetes, Obesity and Metabolism},
  title        = {Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes},
  url          = {http://dx.doi.org/10.1111/j.1463-1326.2009.01079.x},
  volume       = {11},
  year         = {2009},
}